TY - JOUR T1 - A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 1851 LP - 1854 VL - 36 IS - 4 AU - MASAYOSHI NAKANISHI AU - YOSHIAKI KURIU AU - YASUTOSHI MURAYAMA AU - TOMOHIRO ARITA AU - TOSHIYUKI KOSUGA AU - RYO MORIMURA AU - HIROTAKA KONISHI AU - SYUHEI KOMATSU AU - ATSUSHI SHIOZAKI AU - HISASHI IKOMA AU - DAISUKE ICHIKAWA AU - HITOSHI FUJIWARA AU - KAZUMA OKAMOTO AU - EIGO OTSUJI Y1 - 2016/04/01 UR - http://ar.iiarjournals.org/content/36/4/1851.abstract N2 - Aim: Tolerability, adverse events, and long-term outcomes were compared and analyzed between patients receiving oral anticancer agent-based adjuvant chemotherapy regimen (PO group) and those receiving combination adjuvant chemotherapy with oxaliplatin (OX group), after curative resection of colorectal cancer at our Department. Patients and Methods: The subjects included in the study were 169 patients with stage III colorectal cancer who underwent curative resection and received postoperative adjuvant chemotherapy between June 2007 and October 2014. Fifty-three patients were included in the OX group, while 116 patients were included in PO group. Results: No significant difference was observed in treatment completion rates. No significant difference in either the overall or relapse-free survival rates was observed between the two groups. Conclusion: Oxaliplatin has been shown to improve therapeutic outcomes after curative resection of colorectal cancer. Even compared to oral anticancer agents, oxaliplatin appears to be equal in tolerability and treatment completion rate. ER -